---
canonical_name: Ferrous Bisglycinate
alternate_names: Iron Bisglycinate, Ferrous Bisglycinate Chelate, Ferrochel, Iron Bisglycinate Chelate, Ferrous Glycinate, Iron Glycinate, Bis-Glycino Iron II
canonical_topic: Ferrous Bisglycinate for Health & Longevity
short_topic_lc: ferrous_bisglycinate
creation_date: 2026-0823-1121
creator_ai_fullname: Grok 4
---

# Ferrous Bisglycinate for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/23/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4

**Also known as:** Iron Bisglycinate, Ferrous Bisglycinate Chelate, Ferrochel, Iron Bisglycinate Chelate, Ferrous Glycinate, Iron Glycinate, Bis-Glycino Iron II

<!-- Motivation written after all other sections were complete, so it reflects the full scope of the review. -->
  
## Motivation

Ferrous bisglycinate is an oral iron supplement in which iron is bound to two molecules of the amino acid glycine. It is used to refill iron when stores are low — a state that can drain energy, limit oxygen delivery, and cut exercise capacity. Among people who track laboratory panels and train at high load, iron is watched closely because shortage and surplus both carry costs.

The form was built as a better-tolerated alternative to older iron salts and later became common in prenatal formulas and “gentle iron” products. Iron shortage is still the world’s most common nutrient gap, yet extra iron in people who already have full stores is a separate risk. Those two facts sit in tension for anyone treating iron as a longevity tool rather than a short course for documented deficiency.

This review examines how ferrous bisglycinate is absorbed, who gains from it, what harms follow unsupervised use, and how dosing, sourcing, and lab monitoring look in a health-optimization setting. It weighs evidence for refilling stores against the concern that leftover iron, once stores are full, can add chemical stress on tissues.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
  
## Recommended Reading

High-level overviews of ferrous bisglycinate (iron held in a glycine chelate, a small amino-acid ring) and the oral-iron class it belongs to.

<!-- Real-time web search on 2026-08-23 for ferrous bisglycinate / iron bisglycinate / Ferrochel plus priority-expert names (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io) and on-site searches of those platforms. Three items independently discuss ferrous bisglycinate by name or oral-iron repletion in substantial depth. A 2000 meal-absorption trial (Layrisse) was omitted because it is primary research, not a high-level overview. Rhonda Patrick’s Aliquot #137 covers iron shortage versus overload but is members-only and is omitted rather than linked behind a paywall. No Huberman Lab, Chris Kresser, or Lifespan.io piece named the chelate or covered it in depth. -->

- [#297 - AMA #58: Iron: its role in health, testing methods, and strategies for preventing and managing iron deficiency](https://peterattiamd.com/ama58/) - Peter Attia

  A clinician walkthrough of iron testing, deficiency, oral formulations, infusions, and who does not belong on supplemental iron — covering the oral-iron class this chelate belongs to.

- [How to Take Iron Supplements: 8 Tips](https://www.lifeextension.com/wellness/supplements/how-to-take-iron-supplements) - Holli Ryan

  Practical oral-iron timing, form, and safety notes from a dietitian; useful context for how ferrous bisglycinate is taken as an oral iron salt alternative.

- [Iron-deficiency anemia](https://pubmed.ncbi.nlm.nih.gov/25946282/) - Camaschella, 2015

  A clinical review of iron-deficiency anemia: how it is diagnosed, how the body gates absorption, and how oral versus intravenous iron are used.

Rhonda Patrick’s Aliquot #137 on iron shortage versus overload is members-only and is omitted rather than linked behind a paywall. No dedicated Huberman Lab, Chris Kresser, or Lifespan.io content on ferrous bisglycinate was found; those platforms are omitted rather than padded. The remaining candidate was a single meal-absorption trial, not a high-level overview, so the list stops at three.
  
## Grokipedia

<!-- Direct browser retrieval of grokipedia.com on 2026-08-23. Site search for "ferrous bisglycinate" returned a search error; the dedicated article is at https://grokipedia.com/page/Iron_bisglycinate (H1: Iron bisglycinate). -->

- [Iron bisglycinate](https://grokipedia.com/page/Iron_bisglycinate)

  Grokipedia’s dedicated Iron bisglycinate article covers chelate chemistry, absorption versus ferrous sulfate, clinical use in deficiency, and gut tolerability.
  
## Examine

<!-- Direct search of examine.com for "ferrous bisglycinate" on 2026-08-23 (browser hit a checkpoint; recovered via proxy). No dedicated ferrous-bisglycinate monograph. The primary dedicated page is Iron, which names ferrous bisglycinate among oral forms and covers dose, safety, and comparisons. -->

- [Iron](https://examine.com/supplements/iron/)

  Examine’s iron monograph: evidence grades, form comparison including ferrous bisglycinate, dosing ranges, and a safety database covering gut effects and drug binding.
  
## ConsumerLab

<!-- Direct retrieval of consumerlab.com iron review on 2026-08-23. Primary dedicated page is the Iron Supplements Review, which discusses ferrous bisglycinate (including “Gentle Iron”) versus sulfate for food interference and constipation, plus independent product testing. -->

- [Iron Supplements Review (Iron Pills, Liquids and Chews)](https://www.consumerlab.com/reviews/iron-supplements-review/iron/)

  Independent tests of iron products plus a form comparison noting that ferrous bisglycinate is better absorbed with food than ferrous sulfate.
  
## Systematic Reviews

Pooled analyses of ferrous bisglycinate itself and of the oral-iron benefits and gut harms that define its trade-off.

<!-- PubMed searches on 2026-08-23: (ferrous bisglycinate OR iron bisglycinate OR ferrochel OR "ferrous glycinate") AND (systematic review OR meta-analysis); plus oral-iron gastrointestinal systematic reviews. Fischer 2023 is the only SR/MA dedicated to ferrous bisglycinate. Tolkien 2015 and Cancelo-Hidalgo 2013 cover the principal gut-risk trade-off of oral iron. Houston 2018 and Low 2016 cover the main claimed benefits of oral iron (fatigue; anemia/hemoglobin in menstruating women). Mohd Rosli 2021 is polymaltose, not bisglycinate, and was excluded. -->

- [The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/36728680/) - Fischer et al., 2023

  Pooled randomized trials: in pregnancy, bisglycinate raised hemoglobin more than other oral irons and cut gut side effects by about two-thirds.

- [Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/25700159/) - Tolkien et al., 2015

  Meta-analysis: ferrous sulfate more than doubled gut side-effect odds versus placebo, framing the tolerability problem this chelate tries to ease.

- [Tolerability of different oral iron supplements: a systematic review](https://pubmed.ncbi.nlm.nih.gov/23252877/) - Cancelo-Hidalgo et al., 2013

  Broad tolerability review of oral iron salts; gastrointestinal event rates vary widely by formulation, with fumarate among the least tolerated.

- [Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials](https://pubmed.ncbi.nlm.nih.gov/29626044/) - Houston et al., 2018

  In iron-deficient adults without anemia, iron reduced self-reported fatigue but did not improve objective exercise tests.

- [Daily iron supplementation for improving anaemia, iron status and health in menstruating women](https://pubmed.ncbi.nlm.nih.gov/27087396/) - Low et al., 2016

  Cochrane review: daily oral iron in menstruating women lowered anemia risk and raised hemoglobin, with more gastrointestinal complaints than control.
  
## Mechanism of Action

Ferrous bisglycinate is ferrous iron (Fe²⁺) bound to two glycine molecules in a small chelate (molecular weight about 204). In the gut lumen the ring keeps more iron soluble and shrinks the pool of free Fe²⁺ that can irritate mucosa through Fenton chemistry (iron-driven formation of reactive oxygen species).

Two uptake stories exist. Product literature emphasizes intact-chelate uptake through peptide transporter 1 (PEPT1, the intestinal peptide carrier). Cell work is less tidy: knocking out divalent metal transporter 1 (DMT1, the main non-heme iron importer) in human intestinal cells blunted uptake of both ferrous bisglycinate and ferrous sulfate, and human meal studies show the chelate competes for the non-heme iron pathway and is still down-regulated when stores are full. Net reading: DMT1 remains the dominant door; any PEPT1 contribution is secondary.

After uptake, iron joins the labile pool (loosely bound cellular iron), is stored as ferritin (the iron-storage protein) or exported by ferroportin (the only known cellular iron exporter), which hepcidin (the liver hormone that hides ferroportin) gates. Daily oral iron raises hepcidin for about a day, cutting absorption of the next dose. The chelate is not metabolized by cytochrome P450 enzymes (liver enzymes that break down many drugs). Plasma iron typically peaks two to four hours after a dose; there is no conventional drug half-life because absorbed iron is incorporated into hemoglobin (the oxygen-carrying protein in red cells). Tissue distribution follows body iron: hemoglobin, liver ferritin, and muscle myoglobin.
  
## Historical Context & Evolution

Oral iron salts have been used for anemia since the nineteenth century; ferrous sulfate became the cheap clinical standard. Gastrointestinal intolerance and food binding were the recurring complaints. In the 1980s–1990s, Albion Laboratories (now Balchem) patented Ferrochel, a fully reacted ferrous bisglycinate chelate, and published chemistry plus early clinical work. A [1991 crossover trial](https://pubmed.ncbi.nlm.nih.gov/1799918/) in women compared 50 mg elemental iron (the actual iron content, not the weight of the salt) as the chelate versus sulfate and found a preference for the chelate, though moderate-to-severe symptoms still occurred on both. [Meal studies around 2000](https://pubmed.ncbi.nlm.nih.gov/10958812/) reported roughly twofold absorption versus sulfate and partial resistance to phytate (plant compounds that bind iron).

Those early papers often involved company scientists. Independent groups later tested the chelate in pregnancy, infancy, and untargeted community supplementation. World Health Organization anemia programs still center on ferrous sulfate at about 60 mg elemental iron, in part because it is inexpensive and familiar to public payers. Consumer “gentle iron” products then moved bisglycinate into retail, typically at 18–36 mg elemental iron. The current picture is not a settled replacement of sulfate: pregnancy trials often show equal or better hemoglobin at a lower elemental dose with fewer gut complaints, while a [2023 Cambodian trial](https://pubmed.ncbi.nlm.nih.gov/37271416/) in mostly iron-replete women found 18 mg bisglycinate did not match 60 mg sulfate for raising ferritin. Both findings stand; the population and the dose decide which one applies.
  
## Expected Benefits

<!-- Dedicated benefit-profile search on 2026-08-23 via PubMed (ferrous bisglycinate / iron bisglycinate / ferrochel), Cochrane-style oral-iron reviews (anemia, fatigue, athletes, restless legs, cognition), Examine iron monograph, ConsumerLab iron review, and expert oral-iron overviews (Attia AMA 58, Patrick Aliquot 137). Benefits below cover hemoglobin repletion, gut tolerability versus salts, ferritin restoration, fatigue in iron-deficient non-anemic adults, restless legs, exercise capacity, and class-level cognitive outcomes. No human longevity or all-cause-mortality outcome was found for this chelate. Hair, skin, and immune “boosts” in iron-replete users lack controlled human endpoints and are omitted rather than listed as benefits. -->

### High 🟩 🟩 🟩

#### Hemoglobin repletion in iron deficiency

Ferrous bisglycinate raises hemoglobin when iron-deficiency anemia is present. A [meta-analysis of 17 randomized trials](https://pubmed.ncbi.nlm.nih.gov/36728680/) found higher hemoglobin after 4–20 weeks than with other oral irons in pregnant women. Head-to-head trials at 24–25 mg elemental iron matched 50–66 mg of sulfate or fumarate. In children the same meta-analysis found no hemoglobin advantage. The signal is for documented deficiency, not for iron-replete people.

**Magnitude:** About 0.54 g/dL higher hemoglobin than other oral irons in pregnant women over 4–20 weeks; [25 mg](https://pubmed.ncbi.nlm.nih.gov/24152889/) was not inferior to 50 mg sulfate, and [24 mg](https://pubmed.ncbi.nlm.nih.gov/35276810/) compared well with 66 mg fumarate.

#### Fewer gut side effects than iron salts

The chelate’s practical advantage is tolerability. The same [bisglycinate meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36728680/) found fewer gastrointestinal events than other oral irons. A [1991 double-blind crossover](https://pubmed.ncbi.nlm.nih.gov/1799918/) at 50 mg elemental iron still produced moderate-to-severe symptoms in 21% on the chelate versus 37% on sulfate only, with a significant preference for the chelate. This is a relative benefit versus salts, not a claim of zero gut effect.

**Magnitude:** Incidence rate ratio (IRR, a comparison of event rates) 0.36, or 64% fewer gastrointestinal events, versus other oral irons in pooled trials; at 50 mg elemental iron, 21% versus 37% had moderate-to-severe symptoms only on that form.

#### Lower self-reported fatigue when stores are low

Oral iron as a class reduces subjective fatigue in iron-deficient adults who are not anemic, without a matching gain on treadmill or maximal oxygen-uptake (VO₂) tests. That conclusion comes from a [systematic review of 18 trials](https://pubmed.ncbi.nlm.nih.gov/29626044/) (oral and intravenous mixed). A bisglycinate-specific [8-week trial](https://pubmed.ncbi.nlm.nih.gov/37299583/) raised iron labs but did not change mood-scale scores. Fatigue relief tracks repletion, not this chelate form.

**Magnitude:** Standardized mean difference (SMD, a common-unit effect size) −0.38 for self-reported fatigue versus control in iron-deficient non-anemic adults (4 trials, 714 people); no significant mood-scale change in the bisglycinate-only trial.

### Medium 🟩 🟩

#### Restoration of iron stores (ferritin)

Ferritin rises when the chelate is given to people who start low. [Low-dose liquid bisglycinate (27 mg, 8 weeks)](https://pubmed.ncbi.nlm.nih.gov/37299583/) raised ferritin versus placebo in premenopausal women with iron deficiency without anemia. Pregnancy trials show parallel store repletion at 24–25 mg. In mostly iron-replete Cambodian women, 18 mg did not match 60 mg sulfate and was not clearly better than placebo. Store-filling is a deficiency-state effect.

**Magnitude:** Ferritin rose versus placebo with 27 mg for 8 weeks in iron-deficient non-anemic women; [18 mg for 12 weeks](https://pubmed.ncbi.nlm.nih.gov/37271416/) in a mostly replete cohort left mean ferritin 84 μg/L versus 99 μg/L on 60 mg sulfate and 78 μg/L on placebo.

### Low 🟩

#### Restless legs symptoms

Iron repletion can ease restless legs (an urge to move the legs, often at night) when ferritin is low. A meta-analysis of oral or intravenous iron lowered symptom scores. Most strong trials used intravenous iron, so this is class evidence on a better-tolerated oral form.

**Magnitude:** Mean International Restless Legs Syndrome score −3.55 points versus no iron in a [10-trial meta-analysis](https://pubmed.ncbi.nlm.nih.gov/30798983/); driven largely by intravenous ferric carboxymaltose rather than ferrous bisglycinate.

#### Exercise capacity in iron-deficient athletes

Oral iron raises ferritin in very depleted athletes; effects on maximal oxygen uptake (VO₂max) are small. A [2024 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38407751/) found ferritin gains mainly when baseline ferritin was ≤12 μg/L. The performance literature is not bisglycinate-specific.

**Magnitude:** Ferritin rose after 6–8 weeks of 16–100 mg elemental iron/day when baseline ferritin was ≤12 μg/L; VO₂max standardized mean difference 0.49 (not statistically significant).

#### Cognitive performance when stores are low

Oral iron as a class can lift short-term memory and problem-solving in iron-deficient people who are not anemic. A [2025 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40945632/) of randomized trials found those gains; they disappeared when iron-deficient participants were excluded. No bisglycinate-specific cognition trial exists.

**Magnitude:** Standardized mean difference 0.46 for cognitive intelligence and 0.53 for short-term memory versus placebo in that meta-analysis; no attention benefit, and no form-specific bisglycinate data.

### Speculative 🟨

#### Longevity via avoiding deficiency-related energy failure

Iron supports oxygen transport and cell energy, so shortage may drag on healthspan. No trial has tested this chelate on aging; in iron-full adults extra iron is often the worry. Basis is mechanistic only.
  
## Benefit-Modifying Factors

- **HFE and TMPRSS6 variants:** The homeostatic iron regulator gene (HFE) and transmembrane serine protease 6 (TMPRSS6, which helps set hepcidin) change how much oral iron sticks. HFE risk alleles blunt the benefit and raise overload risk; TMPRSS6 iron-refractory alleles can make oral iron fail.

- **Baseline ferritin:** Absorption is inverse to stores. People starting below about 30 ng/mL capture more of each dose; iron-replete users absorb little and mainly raise circulating iron that they do not need.

- **Sex:** Premenopausal women with menstrual loss are the group with repeated randomized-trial gains. Men and postmenopausal women are more often replete; extra iron is then a modifier of risk, not benefit.

- **Gut and inflammatory disease:** Celiac disease, inflammatory bowel disease, *Helicobacter pylori* (a stomach bacterium), and bariatric surgery cut non-heme uptake. The chelate’s food resistance helps some of these settings; active inflammation still raises hepcidin and can block response.

- **Age:** Older adults often have higher hepcidin from low-grade inflammation, so the same milligram dose yields less absorbed iron. Infants and young children absorb well but are not the target of this review.
  
## Potential Risks & Side Effects

<!-- Dedicated side-effect search on 2026-08-23: PubMed for ferrous bisglycinate adverse events, iron overload case reports, gut microbiome secondary analyses; Examine.com Iron safety database (constipation, nausea, drug chelation, pediatric toxicity, oxidative stress); ConsumerLab iron review (gastric discomfort, constipation, 45 mg UL, thyroid-drug warning); Cochrane/Tolkien oral-iron gastrointestinal meta-analyses. Mayo Clinic oral-iron page returned 403; drugs.com “iron supplements” resolved to an intravenous dextran monograph, so oral-iron safety was taken from Examine, ConsumerLab, and primary trials rather than that page. -->

### High 🟥 🟥 🟥

#### Gastrointestinal irritation

Nausea, constipation, diarrhea, bloating, metallic taste, and dark stools remain the dominant adverse events of oral iron, including this chelate. They are less frequent than with ferrous sulfate but not absent. A [bisglycinate meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36728680/) found fewer events versus other irons, while a crossover still recorded moderate-to-severe symptoms on the chelate. Sulfate more than doubled gut-event odds versus placebo, which is why the class is hard to stay on.

**Magnitude:** About 21% of women had moderate-to-severe gut symptoms only on [50 mg chelate](https://pubmed.ncbi.nlm.nih.gov/1799918/) (versus 37% only on sulfate); class-level odds ratio (OR, odds versus control) 2.32 for [ferrous sulfate versus placebo](https://pubmed.ncbi.nlm.nih.gov/25700159/).

#### Binding to other oral drugs and minerals

Iron forms poorly absorbed complexes in the gut with thyroid hormone, tetracyclines, and fluoroquinolones, lowering drug levels. [Levothyroxine](https://pubmed.ncbi.nlm.nih.gov/9191742/) requirements have risen on ferrous sulfate; [ciprofloxacin](https://pubmed.ncbi.nlm.nih.gov/2610494/) absorption fell with ferrous sulfate and zinc-containing multivitamins; [tetracyclines](https://pubmed.ncbi.nlm.nih.gov/946598/) are similarly chelated. Timing separation usually restores exposure. The chelate does not remove this chemistry.

**Magnitude:** Direction is reduced co-administered drug absorption when taken together; literature reports no single percentage that applies across all pairs, and separation of 2–4 hours is the usual workaround.

### Medium 🟥 🟥

#### Accidental pediatric overdose

Elemental iron remains a household poisoning risk. Chelated tablets are easier to take and often look like ordinary supplements, which can lower adult caution. Severe overdose causes corrosive gut injury, shock, and delayed liver failure. This is class toxicology of oral iron, not a bisglycinate-specific signal, and it is dose-dependent.

**Magnitude:** Toxicity risk rises steeply above tens of milligrams of elemental iron per kilogram in a child; adult supplemental intakes are far lower, but one bottle can still be a lethal pediatric dose ([iron poisoning review](https://pubmed.ncbi.nlm.nih.gov/2870463/)).

### Low 🟥

#### Iron overload from unsupervised long-term use

Absorbed iron has no excretory path besides bleeding and cell shedding. Years of Ferrochel produced overload in a mother–daughter pair, with high ferritin, high transferrin saturation (share of iron-carrying protein occupied), and imaging-confirmed tissue iron. Stopping and phlebotomy (therapeutic blood removal) reverse it slowly.

**Magnitude:** In the reported [mother–daughter pair](https://pubmed.ncbi.nlm.nih.gov/39931586/), ferritin and transferrin saturation were high enough to prompt imaging-confirmed tissue iron and about two years of phlebotomy; no trial has defined a population incidence for this chelate.

#### Gut microbiome and pathogen pressure

Unabsorbed iron can feed gut bacteria. In [Cambodian women](https://pubmed.ncbi.nlm.nih.gov/37271416/) on 18 mg bisglycinate for 12 weeks, calprotectin and enteropathogen panels did not differ from placebo. A 16S rRNA sequencing subset (stool bacterial-gene profiles; 172 samples) found higher Enterobacteriaceae. Harm remains plausible in inflammatory bowel disease.

**Magnitude:** No calprotectin or enteropathogen-panel difference versus placebo after 12 weeks of 18 mg in 480 women ([primary trial](https://pubmed.ncbi.nlm.nih.gov/37271416/)); a 172-stool [16S subset](https://pubmed.ncbi.nlm.nih.gov/37199608/) showed higher Enterobacteriaceae and the *bfpA* virulence gene.

### Speculative 🟨

#### Faster tissue aging from mild iron surplus

Work links extra iron to tissue oxidation and brain-iron buildup with age. No controlled study shows this chelate shortens healthspan. The concern is for iron-full people, not short repletion. Basis is mechanistic only.
  
## Risk-Modifying Factors

- **HFE variants:** C282Y homozygosity and compound C282Y/H63D hemochromatosis (inherited iron-overload) alleles remove the usual absorption brake; oral iron then loads organs rather than filling a gap.

- **High baseline ferritin or transferrin saturation:** Starting ferritin above the functional range, or transferrin saturation above about 45%, marks people for whom added oral iron is storage, not therapy.

- **Sex:** Men and postmenopausal women lack menstrual iron loss, so surplus accumulates faster. Premenopausal women have more gut events but also more legitimate demand.

- **Hemoglobin disorders and liver disease:** Thalassemia (inherited low hemoglobin production), sickle cell disease, and cirrhosis already raise iron-loading risk; extra oral iron adds to that burden.

- **Age:** Young children have a narrow overdose margin. Older adults combine higher baseline stores, more polypharmacy, and more hidden gut or other bleeding (occult bleeding) that can be masked if iron is started without investigation.
  
## Key Interactions & Contraindications

- **Levothyroxine (and liothyronine):** Caution. Iron binds thyroid hormone in the gut and can raise thyroid-stimulating hormone. Consequence is under-replacement. Separate by at least 4 hours.

- **Levodopa (carbidopa–levodopa):** Caution. Iron binds this Parkinson disease (a movement disorder) medicine in the gut and cuts blood levels. Consequence is worse motor control. Separate by at least 2 hours.

- **Tetracyclines (doxycycline, minocycline) and fluoroquinolones (ciprofloxacin, levofloxacin):** Caution. Iron chelates these antibiotics and cuts blood levels. Separate by at least 2 hours before or 4–6 hours after iron.

- **Bisphosphonates (alendronate, risedronate):** Caution. Polyvalent iron reduces absorption of these osteoporosis drugs. Separate by several hours; many labels prefer an empty-stomach morning dose of the bisphosphonate alone.

- **Proton pump inhibitors (omeprazole, esomeprazole; acid-blocking drugs) and histamine-2 blockers (famotidine; acid-reducing drugs):** Caution. Low stomach acid reduces ionic iron uptake; the chelate is less pH-dependent than sulfate but is not immune. Monitor ferritin if acid suppression is chronic.

- **Calcium, zinc, and magnesium supplements:** Caution. These minerals compete for absorption and can cut iron uptake. Separate by 2 hours; do not combine a high-dose mineral mix with iron.

- **Tea, coffee, and high-phytate meals:** Caution. Polyphenols still cut Ferrochel absorption (espresso and tea about 50% in meal studies). Vitamin C and meat protein work in the opposite direction.

- **Other iron products and intravenous iron:** Additive. Adding the oral chelate on top of another iron source or a recent infusion raises overload risk. Hold oral iron around infusion days unless a clinician is titrating stores.

- **Vitamin C:** Potentiating. Ascorbate keeps iron reduced and can increase uptake; useful in deficiency, unhelpful once ferritin is full.

**Populations who should avoid Ferrous Bisglycinate:**

- Hereditary hemochromatosis (especially HFE C282Y homozygotes or C282Y/H63D compound heterozygotes) and other primary iron-overload syndromes
- Iron-replete men and postmenopausal women without documented low ferritin or a named ongoing loss
- Active hemolytic or transfusion-dependent iron loading (thalassemia major, similar)
- Uninvestigated anemia in men or postmenopausal women, until bleeding and malabsorption work-up is underway
- Infants and small children as an unsupervised household product (keep bottles locked; this is not a pediatric dosing review)
  
## Risk Mitigation Strategies

- **Confirm deficiency first:** Protocols typically begin only after ferritin, transferrin saturation, complete blood count, and C-reactive protein (a general inflammation marker that can falsely raise ferritin) are known, which prevents treating overload as fatigue.

- **Cap the course:** An 8–16 week course then re-test is the usual pattern; a menstrual-loss maintenance dose is the common step-down once ferritin is in range, which limits slow accumulation.

- **Prefer 18–25 mg elemental iron:** Lower milligram loads cut unabsorbed colonic iron and gut symptoms while remaining effective in deficiency trials.

- **Alternate-day morning dosing:** One daily morning dose, or every other day, cuts unabsorbed colonic iron and gut irritation by avoiding the 24-hour hepcidin bump that wastes a second dose.

- **Time away from binders:** Two to four hours from coffee, tea, calcium, thyroid hormone, and tetracycline or quinolone antibiotics, which preserves both iron uptake and co-drug levels.

- **Child-resistant storage:** Bottles are typically stored locked and away from children; a full bottle can still be a lethal pediatric dose even when adult tablets look mild.

- **Ferritin ceiling:** Recheck at 8–12 weeks is the usual pattern, with the course stopped if ferritin exceeds the functional-range top or transferrin saturation exceeds about 45%, which catches early overload.
  
## Therapeutic Protocol

- **Standard repletion (integrative and sports clinics):** 18–27 mg elemental iron as ferrous bisglycinate once daily, or every other day, for 8–16 weeks in documented deficiency, then re-test (Attia oral-iron AMA; Thorne 25 mg Ferrochel).

- **Conventional hematology alternative:** 50–65 mg elemental iron as ferrous sulfate once daily or every other day remains the WHO guideline default because it is cheap and well studied. Bisglycinate is the tolerability switch, not a different disease target.

- **Pregnancy-style low-dose protocol:** 25 mg elemental bisglycinate daily from the second trimester was not inferior to 50 mg sulfate for preventing deficiency in [Milman’s Danish antenatal trial](https://pubmed.ncbi.nlm.nih.gov/24152889/), with fewer gut complaints.

- **Time of day:** Morning, fasted, when hepcidin is lowest. Evening doses collide with higher hepcidin and with magnesium or calcium often taken at night.

- **Half-life and schedule:** Serum iron peaks in about 2–4 hours; hepcidin stays up ~24 hours. There is no short plasma half-life to chase. Single morning doses beat split daily doses for fractional absorption.

- **Split versus single:** Split and twice-daily regimens raise hepcidin without adding much absorbed iron. One capsule is the usual pattern.

- **Genetics:** HFE risk alleles argue for not starting oral iron without labs, and for a lower ceiling. TMPRSS6 iron-refractory anemia often needs intravenous iron rather than a chelate.

- **Sex:** Premenopausal women with heavy menses often need a longer course or a low maintenance dose after repletion. Men rarely need maintenance.

- **Age:** Older adults typically start at 18–25 mg, with attention to constipation and polypharmacy, and new anemia investigated rather than treated as a nutrient gap.

- **Baseline ferritin:** Repletion is reserved for ferritin <30 ng/mL without inflammation, or <50 ng/mL in a symptomatic, inflamed, or pregnant person. Starting at a “normal-low” value in a replete man treats a lab number, not a gap.

- **Pre-existing conditions:** Celiac disease, bariatric surgery, and inflammatory bowel disease may still respond to the chelate; non-response at 4 weeks is a reason protocols move to intravenous iron rather than raising the milligram dose.
  
## Discontinuation & Cycling

- **Duration:** Repletion is time-limited (typically 8–16 weeks, sometimes 3–6 months if losses continue). It is not a lifelong longevity supplement once stores are full.

- **Withdrawal:** No withdrawal syndrome is described. Fatigue can return if bleeding or low intake continues, which is recurrence of deficiency, not rebound.

- **Taper:** No pharmacologic taper is required. Stopping after a target ferritin is reached is the usual pattern; a step-down to 18 mg on training-heavy or menstrual days is sometimes used when losses persist.

- **Cycling:** Cycling is not used to preserve efficacy. Hepcidin, not receptor down-regulation, gates absorption. Alternate-day dosing during a course is a hepcidin tactic, not an on/off cycle.

- **After stopping:** Recheck ferritin 8–12 weeks after the last dose if losses continue; otherwise at the next routine panel. Rising ferritin after stop is a reason to look for overload or inflammation, not to restart.
  
## Sourcing and Quality

- **True bisglycinate chelate:** Products that name ferrous bisglycinate or Ferrochel (Albion/Balchem) with elemental iron stated in milligrams. “Amino acid chelate” without a defined 1:2 glycine ratio can be a weaker complex.

- **Elemental iron on the label:** Dose decisions use elemental milligrams, not milligrams of chelate salt. Common capsules provide 18, 25, 27, or 36 mg elemental iron.

- **Third-party testing:** NSF Certified for Sport or United States Pharmacopeia / ConsumerLab verification reduces the chance of mis-labeled milligrams or heavy-metal contamination. Thorne Iron Bisglycinate is a frequently cited NSF example.

- **Retail examples:** NOW Foods Ferrochel, Solgar Gentle Iron, Pure Encapsulations, and MegaFood liquid bisglycinate are widely used. ConsumerLab’s iron review is the independent scorecard for a given lot year.

- **Timed-release salts:** Slow-release ferrous sulfate is a different product with weaker absorption. Combining “gentle” marketing with an undeclared sulfate salt is a sourcing miss.

- **Industry bias:** Ferrochel is a branded ingredient; older absorption papers include Albion authors. Independent UBC pregnancy and Cambodia trials are the cleaner efficacy set.
  
## Practical Considerations

- **Time to effect:** Reticulocytes (young red blood cells) move in days; hemoglobin typically rises by 2–4 weeks; ferritin and stores take 8–12 weeks, often 3–6 months if losses continue. Energy shifts, when they occur, usually lag the first hemoglobin bump.

- **Common pitfalls:** Starting without labs; taking iron with coffee, tea, or a calcium tablet; using 65 mg “because more is better”; continuing for years after ferritin normalizes; ignoring non-response as a bleeding or celiac clue.

- **Regulatory status:** In the United States this is a dietary supplement, not an approved drug. Ferrochel is used as a food fortificant. It is not approved by the Food and Drug Administration (FDA) to treat anemia; that use is off-label.

- **Cost and access:** Typical cost is about $0.10–0.30 per day — higher than ferrous sulfate, not a rare-drug barrier. No compounding pharmacy is required.
  
## Interaction with Foundational Habits

- **Sleep:** Direct when restless legs are iron-driven: repletion can cut nocturnal movement. Indirect otherwise. Morning dosing avoids evening gut discomfort that can fragment sleep. No evidence the chelate is sedating or alerting on its own.

- **Nutrition:** Direct. Non-heme uptake rises with vitamin C and meat, and falls with tea, coffee, cocoa, calcium, and phytate-rich grains. A fasted morning capsule with water, then food 30–60 minutes later, is the usual pattern; if the stomach protests, a small low-calcium meal is the compromise.

- **Exercise:** Direct in depleted endurance athletes (red-cell rupture from repetitive foot impact (foot-strike hemolysis), sweat, low intake). Hepcidin rises for hours after hard sessions, so a morning dose on a rest or easy day absorbs better than a post-long-run dose. No evidence the chelate blunts hypertrophy.

- **Stress management:** Indirect. Inflammatory stress raises hepcidin and can lock iron in stores, mimicking deficiency on blood count while ferritin looks “normal.” Training load, illness, and poor sleep all move that hormone; the chelate cannot override a high-hepcidin block.
  
## Monitoring Protocol & Defining Success

Baseline testing is a full iron panel plus inflammation before the first capsule: complete blood count, ferritin, serum iron, total iron-binding capacity or transferrin, transferrin saturation, and C-reactive protein. In men and postmenopausal women, new iron deficiency also triggers a search for blood loss rather than an automatic open-ended supplement. Ongoing monitoring is at 4 weeks if anemia is present (hemoglobin response), at 8–12 weeks for ferritin in non-anemic deficiency, then every 3–6 months if menstrual or training losses continue, or at the next annual panel if the course has stopped and stores are stable. Success is a ferritin in the functional band, transferrin saturation under about 45%, resolution of deficiency symptoms, and no climb into overload.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Ferritin | 50–150 ng/mL | Confirms stores; the treatment on/off switch | Conventional lower limit is often 12–30 ng/mL; inflammation inflates ferritin, so pair with C-reactive protein. Fasting not required. |
| Transferrin saturation | 25–45% | Shows circulating iron available to marrow | Transferrin saturation (TSAT) = serum iron / total iron-binding capacity (TIBC). >45% with high ferritin flags overload. Morning draw; avoid a dose that morning. |
| Hemoglobin | No established target exists; track rise toward the person’s own baseline | Confirms oxygen-carrying recovery | Conventional anemia cutoffs are sex-specific (often ~13.5 g/dL in men, ~12.0 g/dL in women). Expect ~1 g/dL by 2–4 weeks if deficient. Failure at 4 weeks means absorption, ongoing loss, or wrong diagnosis. |
| Mean corpuscular volume | No established target exists; track rise from low toward the lab mid-normal | Tracks iron-limited red-cell production | Mean corpuscular volume (MCV): low supports iron deficiency; high points elsewhere (B12/folate). Part of the complete blood count. |
| C-reactive protein | Low; ideally <1.0 mg/L | Interprets ferritin; high CRP can hide deficiency | C-reactive protein (CRP): conventional upper limit is often <3 or <10 mg/L. If up, ferritin <100 ng/mL can still be iron deficiency. Recheck when well. |
| Soluble transferrin receptor | No single functional target; track fall toward the lab mean | Separates true deficiency from inflammation | Soluble transferrin receptor (sTfR): useful when ferritin and CRP disagree. Not a first-line test. |

Qualitative markers:

- Energy and afternoon stamina relative to the person’s own baseline
- Exercise heart rate and perceived effort at familiar paces
- Restless legs or nocturnal movement
- Hair shedding, brittle nails, and pallor
- Gut comfort on the chosen dose (constipation, nausea, dark stool)

  
## Emerging Research

- **EASE-Iron pregnancy head-to-head:** [NCT06014983](https://clinicaltrials.gov/study/NCT06014983) is recruiting 172 pregnant people randomized to 24 mg ferrous bisglycinate versus 24 mg ferrous fumarate, with ferritin, hemoglobin, and stool microbiome through late pregnancy. A clean same-dose result could strengthen or weaken the “better form at equal milligrams” claim.

- **Untargeted 18 mg versus 60 mg sulfate:** The completed Cambodian trial ([NCT04017598](https://clinicaltrials.gov/study/NCT04017598); [published results](https://pubmed.ncbi.nlm.nih.gov/37271416/)) already weakens low-dose bisglycinate as a one-for-one substitute for 60 mg sulfate in mostly replete populations. Follow-on pathogen and microbiome papers are still appearing.

- **Glycoprotein-matrix iron versus Ferrochel:** [NCT06738199](https://clinicaltrials.gov/study/NCT06738199) and a [2025 crossover](https://pubmed.ncbi.nlm.nih.gov/40190969/) test a newer bound-iron against ferrous bisglycinate. If replicated, the chelate would no longer be the default “best absorbed oral.”

- **Alternate-day dosing of the chelate:** Hepcidin work that favors every-other-day iron used ferrous sulfate ([Stoffel et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29032957/)). Whether bisglycinate needs the same cadence is untested and could change protocol.

- **Brain iron and aging:** Observational and imaging work ([Ward et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25231526/)) on brain-iron accumulation in Parkinson and Alzheimer disease cuts against casual extra iron in replete older adults, even as deficiency remains harmful. That literature is not form-specific.
  
## Conclusion

Ferrous bisglycinate is a glycine-bound oral iron used to refill empty stores, not a general longevity tonic. In people who start deficient — notably premenopausal women and anyone who cannot tolerate older iron salts — trials show it rebuilds the oxygen-carrying protein in blood as well as, and sometimes better than, standard salts, often at a lower milligram dose and with fewer gastrointestinal symptoms. That tolerability gap is why the form exists.

The evidence thins once stores are already full. A low dose did not match a higher dose of an ordinary iron salt at raising stored-iron levels in people who already had enough stored iron. Long-term unsupervised use has produced real overload, including tissue iron on scans. Early absorption papers were tied to the company that sells the branded glycine-bound form; later independent trials are stronger and more mixed. Health systems often choose cheap iron salts — a cost bias, and a reminder that this form is a comfort and continuation tool, not a different mineral.

For a risk-aware adult who already measures stores, the pattern is simple. Low stores and symptoms: this form is a workable oral option. Full stores, male sex after middle age, or iron-loading genes: extra iron is the risk. Evidence is good for blood counts and gut comfort in deficiency, thin for sport performance, restless legs, and memory as form-specific claims, and absent for aging endpoints. Uncertainty lives at the dose and the starting stored-iron level, not in whether iron itself matters.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**